Karyopharm Therapeutics Inc. (KPTI) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Karyopharm Therapeutics Inc. (NASDAQ: KPTI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.88 (+5.73% 1D, market cap $20.0M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, KPTI ranks #823 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KPTI carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, QNRX (Quoin Pharmaceuticals Ltd.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $19.9M) and MCRB (Seres Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $19.6M). Among the 5-stock peer group, KPTI leads on earnings multiple (N/A) while KPTI leads on capital efficiency (-35.0% ROIC).
Per KPTI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001503802), Karyopharm Therapeutics Inc. generated $146.1M in revenue (+0.6% YoY), -$196.0M in net income, and -$75.4M in free cash flow against $108.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While KPTI currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.20) and Max Pain ($0.92) forces dealer call-delta covering toward $11.54.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Karyopharm Therapeutics Inc. (KPTI) surged +5.73% to $0.88, trading at 5% of its 52-week range ($0.31 – $10.99). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Aurinia (AUPH) delivered earnings and revenue surprises of +15.00% and -4.02%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Today's US session featured double-digit moves, with KPTI up 59.38% and JDZG down 77.87% among the largest percentage swings.
Gainers Neumora Therapeutics (NASDAQ:NMRA) shares rose 11.9% to $0.41 during Tuesday's after-market session. The market value of their outstanding shares is at $73.8 million. Pulmonx (NASDAQ:LUNG) stock increased
Gainers Pomdoctor (NASDAQ:POM) shares rose 25.6% to $1.47 during Friday's after-market session. The market value of their outstanding shares is at $8.3 million. GeneDx Holdings (NASDAQ:WGS) shares rose 8.72% to
As previously disclosed in the Current Reports on Form 8-K filed by Karyopharm Therapeutics Inc. (the "Company") on September 11, 2026 and October 14, 2026, the Company entered into a Forbearance Agreement and
Gainers Profusa (NASDAQ:PFSA) shares moved upwards by 35.4% to $1.15 during Thursday's regular session. Karyopharm Therapeutics (NASDAQ:KPTI) shares increased by 29.12% to $0.55. The company's market cap
Gainers Vivos Therapeutics (NASDAQ:VVOS) stock increased by 17.9% to $0.16 during Monday's after-market session. The market value of their outstanding shares is at $2.8 million. SCWorx (NASDAQ:WORX) shares moved
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +0.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on KPTI today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for KPTI. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Karyopharm Therapeutics Inc. (KPTI) ranks #823 by composite RQD confidence (31/100, grade E) and #833 by equity capitalization ($20.0M). Within this direct 5-issuer industry benchmark cohort, KPTI leads on earnings valuation at N/A trailing P/E, while KPTI leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. QNTM currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with KPTI at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| KPTI
ACTIVE
Karyopharm Therapeutics Inc. | E | 31/100 | — | — | -35.0% | +5.73% | $20.0M | Benchmark Subject |
| QNRX Quoin Pharmaceuticals Ltd. | D- | 35/100 | — | — | -35.0% | +0.97% | $19.9M | /qnrx-vs-kpti → |
| MCRB Seres Therapeutics Inc. | D- | 40/100 | — | — | -35.0% | +8.94% | $19.6M | /mcrb-vs-kpti → |
| ACTU Actuate Therapeutics Inc. | D- | 35/100 | — | — | -35.0% | -3.21% | $20.4M | /actu-vs-kpti → |
| QNTM Quantum Biopharma Ltd. Class B Subordinate Voting Shares | D | 46/100 | — | — | — | +2.95% | $20.7M | /qntm-vs-kpti → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Karyopharm Therapeutics Inc. (KPTI) reported GAAP revenue of $146.1M (+0.6% vs. FY2024 revenue of $145.2M , and +0.0% cumulative change since FY2023) , GAAP net income of -$196.0M, operating cash flow of -$75.4M, and free cash flow of -$75.4M (+40.9% YoY). On the balance sheet, KPTI closed FY2025 with $108.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $146.1M | -$196.0M | -$75.4M | -$75.4M | $108.4M | — |
| FY2024 (FY) | 2024-12-31 | $145.2M | -$76.4M | -$127.5M | -$127.6M | $164.4M | — |
| FY2023 (FY) | 2023-12-31 | $146.0M | -$143.1M | -$92.7M | -$92.7M | — | — |
As of 2026-11-02, Karyopharm Therapeutics Inc. (NASDAQ: KPTI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.88 (+5.73% 1D, market cap $20.0M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, KPTI ranks #823 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KPTI carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, QNRX (Quoin Pharmaceuticals Ltd.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $19.9M) and MCRB (Seres Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $19.6M). Among the 5-stock peer group, KPTI leads on earnings multiple (N/A) while KPTI leads on capital efficiency (-35.0% ROIC).
Per KPTI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001503802), Karyopharm Therapeutics Inc. generated $146.1M in revenue (+0.6% YoY), -$196.0M in net income, and -$75.4M in free cash flow against $108.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
KPTI last traded at $0.88 (+5.73% on volume of 6,845,561 shares), positioning the stock -26.67% below its 50-day simple moving average ($1.20) and -85.36% below its 200-day simple moving average ($6.01). Across its 52-week range of $0.31 to $10.99, KPTI sits at the 5.3% percentile with a 14-day RSI of 51.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.99).
Why KPTI Stock surged +5.73% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).